Piramal Pharma has started work on the expansion of its Lexington, Kentucky factory. Piramal Pharma held a groundbreaking ceremony at the plant on June 25, 2025, to mark this key milestone and the company’s future expansion.
This investment comes at a crucial time for the sterile injectables business, which is growing quickly because of more medical need, more regulatory approvals, and big strides in scientific research and development. Also, the simple delivery methods that come with sterile injectables make them more effective and safe, which is why they are becoming more popular with both healthcare practitioners and consumers. In the same way, ADC treatments are becoming more popular because of new ideas, more acceptability by regulators, and strong proof that they work. The increasing use of ADCs shows how important it is to improve production and research skills to keep up with the changing needs of patient care.
This investment puts Piramal Pharma in a good position to take advantage of these developments. It will help the firm satisfy the growing demand for both sterile injectables and ADC treatments while also giving it a competitive edge in the market. After the expansion is done in late 2027, the Lexington facility will be able to make more than twice as many products, going from 104 batches per year (during peak use) to more than 240 batches per year.
“We prioritize patient, consumer, and customer centricity in all our operations, engaging with the populations we serve to better understand, anticipate, and address their needs. Our research has revealed that the sterile injectables market is projected to exceed $20B by 2028, underscoring the urgent need for us to enhance our offerings in this segment. We are confident that this strategic $90M investment will empower us to meet the demands of this market, reinforcing our position as a trusted global partner in biologic manufacturing. By enhancing the services we provide to our partners, we can reduce the burden of disease for more patients around the globe,” said Nandini Piramal, Chairperson, Piramal Pharma.
“As the market adjusts and preferences shift, we are committed to adapting to meet its current requirements,” said Peter DeYoung, Chief Executive Officer, Piramal Global Pharma. “ADCs are rapidly emerging as one of the most effective classes of precision immunotherapy targeting certain cancers and tumors. As this class of drugs becomes more prevalent, we will adapt our services to accommodate this growing demand. By investing in the Lexington and Riverview facilities, we will enhance our integrated ADC offering, ADCelerate™, and increase our capacity to bring high-quality, innovative treatments to our clients and their patients worldwide.”
The development of the Lexington plant is also an investment in the local community since it will create 40 new full-time positions that will boost the economy and expand Piramal Pharma’s staff. Piramal Pharma will keep working with local partners to use the area’s assets to be at the cutting edge of new ideas. This investment also fits with the expanding trend of U.S. onshore manufacturing, which shows the company’s commitment to making things in the U.S. and keeping its supply chain strong.
At the groundbreaking ceremony, Lexington Mayor Linda Gorton expressed her excitement about the project and the promising opportunities it presents for the city, stating, “Piramal’s decision to expand its facility here in Lexington sends a message around the world that Lexington is a great place to do business. Lexington is home to one of the nation’s best pharmacy programs – the University of Kentucky College of Pharmacy – and we are well on our way to becoming a leader in the pharmaceutical industry, as well.”
Others echoed Mayor Gorton’s sentiment with equal enthusiasm, including Jim Stephanou, CEO of IPS-Integrated Project Services, who said, “IPS is a proud supporter of Piramal’s growth over the past five years, providing fit-for-purpose solutions on transformative projects across India, the UK, Canada, and the U.S. Our longstanding relationship is built on trust and a relentless commitment to technical excellence. Nothing is more rewarding than seeing shovels in the ground, especially here in Lexington. This groundbreaking highlights our deep expertise in Aseptic Fill/Finish facilities, and our passion to help Piramal bring this advanced manufacturing facility to life to deliver critical therapies to patients around the world.”
Commerce Lexington President and CEO, Bob Quick, said, “We are proud to celebrate this milestone moment with Piramal and excited for its continued growth and success. Biotech is a key strategic target for Greater Lexington economic development professionals, and this expansion will further strengthen the region as a hub for biotech and life sciences. Piramal’s investment highlights the advantages of the area as an exceptional place where innovative companies come to grow and thrive.”
Piramal Pharma Solutions’ $90 million investment in its U.S. facilities is a big step forward in its production capabilities and shows that it is still committed to putting patients first. This strategic decision will help Piramal Pharma keep up with the changing requirements of the healthcare industry. It will put the firm at the top of the quickly rising sterile injectables and ADC sectors, which will be good for patients and communities alike.
